Kazia Therapeutics Ltd (KZIA) FinancialsKZIAKazia Therapeutics Ltd

Kazia Therapeutics Ltd (KZIA) generates its revenue primarily from Consumer Business, which accounts for 100.0% of total sales, equivalent to $10.31K. Understanding this concentration is critical for investors evaluating how KZIA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Kazia Therapeutics Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8320.33%, while the net margin is -7800.31%. These profitability ratios, combined with a Return on Equity (ROE) of -102.73%, provide a clear picture of how effectively KZIA converts its operational activities into shareholder value.

In the context of the broader market, KZIA competes directly with industry leaders such as EQ and UNCY. With a market capitalization of $155.18M, it holds a leading position in the sector. When comparing efficiency, KZIA's gross margin of 100.00% stands against EQ's N/A and UNCY's N/A. Such benchmarking helps identify whether Kazia Therapeutics Ltd is trading at a premium or discount relative to its financial performance.

The company has a forward P/E of 12.82, indicating a favorable valuation compared to its expected earnings growth. Despite a negative P/E ratio of -3.41, the forward metrics suggest potential profitability as clinical trials progress.